2018 Stevenson Biomaterials Lecture Series

A T  S Y R A C U S E  U N I V E R S I T Y

Stevenson Biomaterials Lecture & Research Poster Session
Life Sciences Complex Atrium
Friday, March 2, 2018
Poster Session: 10:30 a.m. to 12:00 a.m.
Luncheon: 12:15 p.m. to 1:00 p.m.
Lecture: 1:15 p.m. to 2:15 p.m. (LSB001 Auditorium)
Poster Competition Awards & Prizes announced following luncheon.

Event Registration
Stevenson Biomaterials Lecture & Luncheon
Please Register Here
by Monday, February, 26
Need Parking Arrangements? Please contact Karen Low at 315-443-3544

2018 Stevenson Biomaterials Lecturer

Thomas J. Webster
Art Zafiropoulo Chair, Chemical Engineering Department Chair
Northeastern University
Fellow, AANM, AIMBE, BMES, FSBE, and NAI
Editor, International Journal of Nanomedicine
Associate Editor, Nanomedicine: NBM
Recently named Fellow of National Academy of Inventors

Presentation:
Two Decades of Commercializing Medical Devices Using Nanotechnology: The FDA is Approving Nanomedicine Products !

Abstract
There is an acute shortage of organs due to disease, trauma, congenital defects, and most importantly, age related maladies. The synthetic materials used in tissue engineering applications today are typically composed of millimeter or micron sized particles and/or fiber dimensions. Although human cells are on the micron scale, their individual components, e.g. proteins, are composed of nanometer features. By modifying only the nanofeatures on material surfaces without changing surface chemistry, it is possible to increase tissue growth of any human tissue by controlling the endogenous adsorption of adhesive proteins onto the material surface. In addition, our group has shown that these same nanofeatures and nano-modifications can reduce bacterial growth without using antibiotics, which may further accelerate the growth of antibiotic resistant microbes. Inflammation can also be decreased through the use of nanomaterials. Finally, nanomedicine has been shown to stimulate the growth and differentiation of stem cells, which may someday be used to treat incurable disorders, such as neural damage. This strategy also accelerates FDA approval and commercialization efforts since new chemistries are not proposed, rather chemistries already approved by the FDA with altered nanoscale features. This invited talk will highlight some of the advancements and emphasize current nanomaterials approved by the FDA for human implantation.

 

Comments are closed.